Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30370553 | 1.00 | KDM4E (0.55) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL29174222 | 0.89 | KDM4E (0.46) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL1140140 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL30411552 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL29174283 | 0.81 | RECQL (0.39) | KDM4ERECQLHTTALDH1A1HPGD | |
| SCHEMBL1909362 | 0.80 | KDM4E (0.43) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL17782879 | 0.80 | KDM4E (0.52) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL1911795 | 0.80 | KDM4E (0.44) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL3639155 | 0.80 | L3MBTL1 (0.54) | KDM4EMEN1KMT2ARECQLHTT | |
| SCHEMBL554234 | 0.79 | KDM4E (0.42) | KDM4EMEN1KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303047-B | Synthesis method of 2-amino-4, 6-lutidine | 上海阿拉丁生化科技股份有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-111303047-A | Synthesis method of 2-amino-4, 6-dimethylpyridine | 上海阿拉丁生化科技股份有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-111303047-B | Synthesis method of 2-amino-4, 6-lutidine | 上海阿拉丁生化科技股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| EP-0284229-B1 | NONLINEAR OPTICAL MATERIAL AND METHOD FOR ORIENTATION THEREOF | CANON KABUSHIKI KAISHA (JP) | 1993-07-21 | — | — | EP | disclosed |
| US-5037582-A | Nonlinear optical material and method for orientation thereof | CANON KABUSHIKI KAISHA (JP) | 1991-08-06 | — | — | US | disclosed |
| US-4946261-A | Recording method and recording apparatus | CANON KABUSHIKI KAISHA (JP) | 1990-08-07 | — | — | US | disclosed |
| US-4882715-A | Surface acoustic wave convolver with dielectric film of high non-linear effect | CANON KABUSHIKI KAISHA (JP) | 1989-11-21 | — | — | US | disclosed |
| EP-0295145-A2 | Recording method and recording apparatus | CANON KABUSHIKI KAISHA (JP) | 1988-12-14 | — | — | EP | disclosed |
| EP-0284229-A1 | Nonlinear optical material and method for orientation thereof | CANON KABUSHIKI KAISHA (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0282978-A2 | Surface acoustic wave convolver with dielectric film of high non-linear effect | CANON KABUSHIKI KAISHA (JP) | 1988-09-21 | — | — | EP | disclosed |
| US-4098893-A | PYRIDINE DERIVATIVES AND THEIR USE AS ANTICOCCIDIAL AGENTS | SANKYO COMPANY LIMITED (JP) | 1978-07-04 | — | — | US | disclosed |
| US-4054663-A | POULTRY FEEDS | SANKYO COMPANY LIMITED (JA) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | KDM4E 4324/4885MEN1 498/4885KMT2A 4590/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KDM4E 838/4885MEN1 662/4885KMT2A 1570/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MEN1 590/4885KMT2A 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.